View:
Download DOC
Download PDF
Download XLS

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13D

 

Under the Securities Exchange Act of 1934
(Amendment No. 4)*

 

Oncobiologics, Inc.

(Name of Issuer)

 

Common Stock, par value $0.01 per share

(Title of Class of Securities)

 

68235M105

(CUSIP Number)

 

BioLexis Pte. Ltd.

36 Robinson Road

#13-01 City House

Singapore, 068877

ATTN: Executive Director

Telephone: +962 6 582 7999 (ext. 1104)

 

with a copy to:

 

Shearman & Sterling LLP

599 Lexington Avenue

New York, NY 10022

Attn: Brien Wassner

(212) 848-4000

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

 

November 7, 2018

(Date of Event Which Requires Filing of This Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

 

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 
CUSIP No. 68235M105		 13D Page    2   of     13    Pages
1.

Names of Reporting Persons

BioLexis Pte. Ltd.

  
2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

(a) ¨

(b) x

  
3. SEC USE ONLY  
4.

SOURCE OF FUNDS

 

WC

  
5. CHECK B IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)  ¨  
6.

CITIZENSHIP OR PLACE OF ORGANIZATION

Singapore

  

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON WITH:

 7.

SOLE VOTING POWER

0

  
8.

SHARED VOTING POWER

 

99,296,382 (1)

  
9.

SOLE DISPOSITIVE POWER

0

 
10.

SHARED DISPOSITIVE POWER

99,296,382 (1)

  
11.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

99,296,382 (1)

  
12.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

¨

  
13.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

78.1% (2)

  
14.

TYPE OF REPORTING PERSON

IV

  
               
(1)Includes (1) an aggregate of 60,383 shares of Series A-1 Convertible Preferred Stock (“Preferred Stock”) of Oncobiologics, Inc., a Delaware corporation (the “Issuer”), which converts into an aggregate of 9,128,931 shares of common stock of the Issuer (“Shares”), and (2) warrants to purchase an aggregate of 37,262,820 Shares.
(2)This percentage is calculated based upon 72,198,468 Shares outstanding as set forth in the Issuer’s Quarterly Report on Form 10-Q for the period ending June 30, 2018, as filed with the Securities and Exchange Commission on August 14, 2018, plus (1) the 8,577,248 Shares acquired by BioLexis Pte. Ltd. (“BioLexis”) on November 7, 2018, (2) warrants to purchase an aggregate of 37,262,820 Shares, and (3) 9,128,931 Shares underlying the Preferred Stock.

 

 

 


CUSIP No. 68235M105		 13D Page   3   of    13    Pages  
1.

Names of Reporting Persons

Ghiath M. Sukhtian

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

(a) ¨

(b) x

3. SEC USE ONLY
4.

SOURCE OF FUNDS

 

N/A

5. CHECK B IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)  ¨
6.

CITIZENSHIP OR PLACE OF ORGANIZATION

Jordan

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON WITH:

 7.

SOLE VOTING POWER

0

8.

SHARED VOTING POWER

 

99,296,382 (1)

9.

SOLE DISPOSITIVE POWER

0

10.

SHARED DISPOSITIVE POWER

99,296,382 (1)

11.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

99,296,382 (1)

12.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

¨

13.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

78.1% (2)

14.

TYPE OF REPORTING PERSON

IN

             
(1)Includes (1) an aggregate of 60,383 shares the Preferred Stock, which converts into an aggregate of 9,128,931 Shares, and (2) warrants to purchase an aggregate of 37,262,820 Shares.
(2)This percentage is calculated based upon 72,198,468 Shares outstanding as set forth in the Issuer’s Quarterly Report on Form 10-Q for the period ending June 30, 2018, as filed with the Securities and Exchange Commission on August 14, 2018, plus (1) the 8,577,248 Shares acquired by BioLexis on November 7, 2018, (2) warrants to purchase an aggregate of 37,262,820 Shares, and (3) 9,128,931 Shares underlying the Preferred Stock.

  

 

 

 
CUSIP No. 68235M105		 13D Page    4   of   13     Pages
1.

Names of Reporting Persons

Arun Kumar Pillai

  
2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

(a) ¨

(b) x

  
3. SEC USE ONLY  
4.

SOURCE OF FUNDS

 

N/A

  
5. CHECK B IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)  ¨  
6.

CITIZENSHIP OR PLACE OF ORGANIZATION

India

  

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON WITH:

 7.

SOLE VOTING POWER

0

  
8.

SHARED VOTING POWER

 

99,296,382 (1)

  
9.

SOLE DISPOSITIVE POWER

0

 
10.

SHARED DISPOSITIVE POWER

99,296,382 (1)

  
11.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

99,296,382 (1)

  
12.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

¨

  
13.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

78.1% (2)

  
14.

TYPE OF REPORTING PERSON

IN

  
               
(1)Includes (1) an aggregate of 60,383 shares the Preferred Stock, which converts into an aggregate of 9,128,931 Shares, and (2) warrants to purchase an aggregate of 37,262,820 Shares.
(2)This percentage is calculated based upon 72,198,468 Shares outstanding as set forth in the Issuer’s Quarterly Report on Form 10-Q for the period ending June 30, 2018, as filed with the Securities and Exchange Commission on August 14, 2018, plus (1) the 8,577,248 Shares acquired by BioLexis on November 7, 2018, (2) warrants to purchase an aggregate of 37,262,820 Shares, and (3) 9,128,931 Shares underlying the Preferred Stock.

 

 

 

  


CUSIP No. 68235M105		   Page    5   of     13   Pages

 

This Amendment No. 4 (“Amendment No. 4”) to Schedule 13D supplements and amends the statement on Schedule 13D of BioLexis Pte. Ltd. (formerly known as GMS Tenshi Holdings Pte. Limited), a Singapore private limited company (“BioLexis”), Ghiath M. Sukhtian (“Sukhtian”), and Arun Kumar Pillai (“Kumar”) originally filed with the Securities and Exchange Commission (the “SEC”) on September 18, 2017 (the “Original Schedule 13D”), and amended by Amendment Nos. 1, 2 and 3 thereto, filed with the SEC on each of November 1, 2017, June 25, 2018 and July 20, 2018, respectively (together the “Schedule 13D”). Except as otherwise specified in this Amendment No. 4, all items in the Schedule 13D remain unchanged. All capitalized terms used herein and not otherwise defined have the meanings ascribed to such terms in the Original Schedule 13D.

 

The Reporting Persons are filing this Amendment No. 4 to report BioLexis’s private purchase of 8,577,248 Shares in connection with the November 2018 Purchase Agreement (as described below).

 

Item 1.Security and Issuer.

 

 

The Schedule 13D relates to the common stock, par value $0.01 per share (the “Shares”), of Oncobiologics, Inc., a Delaware corporation (the “Issuer”), with its principal executive offices located at 7 Clarke Drive, Cranbury, New Jersey 08512.  The Shares are listed on the Nasdaq Capital Market under the ticker symbol “ONS”.  Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

 

Item 2.Identity and Background.

 

(a)This Amendment No. 4 is being filed by BioLexis, Sukhtian, and Kumar (collectively, the “Reporting Persons”).

 

(b)–(c)Tenshi Life Sciences Private Limited (“Tenshi”), a private investment vehicle of Kumar, and GMS Pharma (Singapore) Pte. Limited (“GMS Pharma”), a private investment company and wholly-owned subsidiary of GMS Holdings, a private investment company (“GMS Holdings”), are the 50:50 beneficial owners of BioLexis in which each of Tenshi and GMS Pharma owns 50% of the outstanding voting shares. Kumar, a natural person, is the holder of a controlling interest in Tenshi. Sukhtian, a natural person, is the holder of a controlling interest in GMS Holdings, which is the holder of a controlling interest in GMS Pharma.

 

The principal office address of BioLexis is 36 Robinson Road, #13-01, City House, Singapore 068877. The principal office address of Kumar is #30, “Galaxy”, 1st Main, J.P. Nagar, 3rd Phase, Bangalore, India 560078. The principal office address of Sukhtian is Zahran Street, 7th Circle Zahran Plaza Building, 4th Floor P.O. Box 142904, Amman, Jordan 11844.

 

 

 

 


CUSIP No. 68235M105		   Page    6   of    13    Pages

  

The directors and executive officers of BioLexis are set forth on Schedule I attached hereto. Schedule I sets forth the following information with respect to each such person:

 

(i)name;

 

(ii)business address;

 

(iii)present principal occupation or employment and the name, principal business and address of any corporation or other organization in which such employment is conducted; and

 

(iv)citizenship.

 

(d)–(e)  None of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). None of the Reporting Persons has, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and, as a result of such proceeding, was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

 

(f)(i)  Kumar is a citizen of India.

 

(ii)Sukhtian is a citizen of Jordan.

 

Item 3.Source and Amount of Funds or Other Consideration.

 

On November 5, 2018, BioLexis entered into a purchase agreement with the Issuer (the “November 2018 Purchase Agreement”) pursuant to which BioLexis agreed to purchase, in a private placement (the “Private Placement”), up to $20.0 million of Shares. On November 7, 2018, the Issuer closed the initial sale of 8,577,248 Shares to BioLexis for an aggregate purchase price of $8.0 million, and amended its Investor Rights Agreement (as defined below) with BioLexis, as described below.   The remaining $12.0 will fund in three equal tranches on each of December 3, 2018, January 3, 2019 and February 1, 2019, subject to customary closing conditions and achievement of certain funding milestones as set forth in the November 2018 Purchase Agreement. The source of funds for such purchases was the working capital of BioLexis and capital contributions made to BioLexis.

 

Item 4.Purpose of Transaction

 

The Issuer intends to use the net proceeds from the Private Placement primarily for (i) clinical trials for its lead product candidate, ONS-5010, and (ii) for working capital and general corporate purposes, including the agreed repayments on the senior secured notes.

 

This Schedule 13D relates to the acquisition of the Shares and other securities of the Issuer by the Reporting Persons. The securities acquired by the Reporting Persons were acquired for the purpose of making an investment in the Issuer.

 

 

 

 


CUSIP No. 68235M105		   Page    7   of    13    Pages

 

Except as set forth in this Schedule 13D, the Reporting Persons have not formulated any plans or proposals which relate to or would result in: (a) the acquisition by any person of additional securities of the Issuer or the disposition of securities of the Issuer; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of the assets of the Issuer or any of its subsidiaries; (d) any change in the present Board or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) any material change in the Issuer’s capitalization or dividend policy of the Issuer; (f) any other material change in the Issuer’s business or corporate structure; (g) any change in the Issuer’s charter or bylaws or other instrument corresponding thereto or other action which may impede the acquisition of control of the Issuer by any person; (h) causing a class of the Issuer’s securities to be deregistered or delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act; or (j) any action similar to any of those enumerated above.

 

Item 5.Interest in Securities of the Issuer

 

(a)–(b) As of the date of this filing, the Reporting Persons may be deemed, for purposes of Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), directly or indirectly, including by reason of their mutual affiliation, to be the beneficial owners of the Shares described in Item 6 below. Based upon information contained in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 14, 2018, together with the 8,577,248 shares acquired pursuant to the November 2018 Purchase Agreement, such Shares deemed to be indirectly beneficially owned by the Reporting Persons constitutes approximately 78.1% of the issued and outstanding Shares. Sukhtian, as the holder of a controlling interest in GMS Holdings, the holder of a controlling interest in GMS Pharma, which owns 50% of the outstanding voting shares of BioLexis, may be deemed to indirectly beneficially own the Shares held by BioLexis. Kumar, as the holder of a controlling interest in Tenshi, which owns 50% of the outstanding voting shares of BioLexis, may also be deemed to indirectly beneficially own the Shares held by BioLexis. As a result, Kumar and Sukhtian share the power to direct the vote and to direct the disposition of the Shares described in Item 6 below.

 

(c)On September 30, 2018, BioLexis received a regular quarterly dividend of 1,648 shares of Preferred Stock pursuant to the terms of such Preferred Stock.

 

(d)Not applicable.

 

(e)Not applicable

 

Item 6.Contracts, Arrangements, Understandings or Relationships with respect to Securities of the Issuer

 

Tenshi, a private investment vehicle of Kumar, and GMS Pharma, a private investment company and wholly-owned subsidiary of GMS Holdings, are the 50:50 beneficial owners of BioLexis, in which each of Tenshi and GMS Pharma owns 50% of the outstanding voting shares. Kumar, a natural person, is the holder of a controlling interest in Tenshi. Sukhtian, a natural person, is the holder of a controlling interest in GMS Holdings, which is the holder of a controlling interest in GMS Pharma. By virtue of such relationships, Kumar and Sukhtian may be deemed to have voting and investment power with respect to the securities held by BioLexis noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. As of the date of this Schedule 13D, the number of Shares attributable to BioLexis (assuming conversion of the Preferred Stock and warrants to purchase Shares (“Warrants”) acquired by BioLexis) is 99,296,382. Kumar and Sukhtian may also each be considered to hold indirectly the same 99,296,382 Shares.

 

 

 

 


CUSIP No. 68235M105		   Page    8   of   13     Pages

 

Pursuant to the Investor Rights Agreement (as defined below), BioLexis was granted the right to appoint four representatives to the Issuer’s Board of Directors (the “Board”), and accordingly, the Reporting Persons may have the ability to affect and influence control of the Issuer. BioLexis has designated four representatives to serve on the Board.

 

November 2018 Purchase Agreement

 

Item 3 above summarizes certain provisions of the November 2018 Purchase Agreement and is incorporated herein by reference. The description of the November 2018 Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the November 2018 Purchase Agreement, a copy of which is attached as Exhibit 9 to this Schedule 13D, and is incorporated herein by reference.

 

Voting and Lockup Agreements

 

Prior to and in connection with the purchase agreement entered into between the Issuer and BioLexis on September 11, 2017 (the “2017 Purchase Agreement”), on September 7, 2017, BioLexis entered into voting and lock-up agreements with Lawrence A. Kenyon, the Issuer’s Chief Financial Officer and interim Chief Executive Officer, and Kenneth M. Bahrt, M.D., the Issuer’s Chief Medical Officer, as well as the members of the Board (other than Pankaj Mohan, Ph.D., a member of the Board and the Issuer’s former Chairman and Chief Executive Officer) (collectively, the “Voting Agreements”) whereby they agreed to vote in favor of the proposals to issue the securities to BioLexis pursuant the 2017 Purchase Agreement and the change in control of the Issuer. Dr. Mohan entered into a separate lock-up agreement with BioLexis (the “Lock-Up Agreement”). Pursuant to the Voting Agreements and the Lock-Up Agreement, the lock-up period for the Issuer’s executive officers and the members of Board who will continue on the Board after the closing of the sale of the remaining securities pursuant to the 2017 Purchase Agreement, including Dr. Mohan, is 12 months, and the lock-up period for the members of the Board who resigned from the Board in connection with the 2017 Purchase Agreement was nine months.

 

Pursuant to the Voting Agreements and Lock-Up Agreement, during such lock-up periods, the parties have agreed not to, except in limited circumstances, (i) sell, transfer, pledge, assign or otherwise encumber or dispose of any of the securities (as such term is defined in the Voting Agreements and Lock-Up Agreement), or enter into any agreement, option or other arrangement or understanding with respect to any of the securities, (ii) deposit any securities into a voting trust or enter into any voting arrangement with respect to the securities, or (iii) take any other action that would in any way make any representation or warranty of the stockholder signatory untrue or incorrect in any material respect or otherwise restrict, limit or interfere in any material respect with the performance of such stockholder’s obligations under such agreement or the transactions contemplated by such agreement.

 

 

 

 


CUSIP No. 68235M105		   Page    9   of     13    Pages

 

The foregoing descriptions of the Voting Agreements and the Lock-Up Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of such agreements, copies of which are filed as Exhibits 2, 3 and 4 and incorporated herein by reference.

 

Investor Rights Agreement

 

On September 11, 2017, the Issuer entered into an investor rights agreement with BioLexis (the “Investor Rights Agreement”) in connection with the 2017 Purchase Agreement. Pursuant to the Investor Rights Agreement, the Issuer granted BioLexis certain registration rights with respect to the Shares issuable upon conversion of the Series A Convertible Preferred Stock and exercise of the Warrants, Board designation rights, piggyback registration rights and information rights, as well as the right of first offer over future issuances of securities and a right of participation in future securities issuances. The Issuer also agreed not to file any registration statement to register for resale the sale of any securities of a third party without BioLexis’ prior consent.

 

Additionally, the Issuer agreed to appoint up to four new directors to be designated by BioLexis, such that BioLexis’ designees represent a majority of the Board. As long as BioLexis maintains beneficial ownership of at least 5% of the Issuer’s outstanding Shares, it shall be entitled to nominate directors to the Board in proportion to its ownership stake in the Issuer. As long as BioLexis maintains beneficial ownership of at least 50% of the Issuer’s outstanding Shares but less than or equal to 57%, BioLexis shall be entitled to nominate a majority of the directors for election to the Board.

 

In connection with the purchase agreement entered into between the Issuer and BioLexis on May 11, 2018 (the “2018 Purchase Agreement”), the Issuer and BioLexis amended the Investor Rights Agreement in order to provide BioLexis certain registration and other rights with respect to the Shares acquired pursuant to the 2018 Purchase Agreement and the Shares that may be issuable upon exercise of the Warrants acquired pursuant to the 2018 Purchase Agreement (the “Investor Rights Agreement Amendment No. 1”).

 

In connection with the exchange agreement entered into between the Issuer and BioLexis on July 18, 2018 (the “Exchange Agreement”), the Issuer and BioLexis amended the Investor Rights Agreement in order to provide BioLexis certain registration and other rights with respect to the Shares that may be issuable upon conversion of the Preferred Stock acquired pursuant to the Exchange Agreement (the “Investor Rights Agreement Amendment No. 2”).

 

In connection with the November 2018 Purchase Agreement, the Issuer and BioLexis amended the Investor Rights Agreement in order to provide BioLexis certain registration and other rights with respect to the Shares acquired pursuant to the November 2018 Purchase Agreement (the “Investor Rights Agreement Amendment No. 3”).

 

 

 

 


CUSIP No. 68235M105		   Page    10   of     13    Pages

 

The foregoing descriptions of the Investor Rights Agreement, the Investor Rights Agreement Amendment No. 1, the Investor Rights Agreement Amendment No. 2 and the Investor Rights Agreement Amendment No. 3, do not purport to be complete and are qualified in their entirety by reference to the full text of the Investor Rights Agreement, the Investor Rights Agreement Amendment No. 1, the Investor Rights Agreement Amendment No. 2 and the Investor Rights Agreement No. 3, copies of which are filed as Exhibits 5, 6, 8 and 10 to this Schedule 13D, and incorporated herein by reference.

 

Item 7.Material to be Filed as Exhibits

 

ExhibitDescription

 

1.Joint Filing Agreement, among GMS Tenshi Holdings Pte. Limited, Ghiath M. Sukhtian, and Arun Kumar Pillai, dated November 9, 2018.

 

2.Form of Voting and Lock-up Agreement by and between GMS Tenshi Holdings Pte. Limited and the Director or Executive Officer of Oncobiologics, Inc. party thereto, dated September 7, 2017 (incorporated by reference to Exhibit 10.4 to the Issuer’s Form 8-K (SEC File No. 001-37759), filed with the SEC on September 11, 2017).

 

3.Voting and Lock-up Agreement by and between GMS Tenshi Holdings Pte. Limited and Todd Brady, Director Oncobiologics, Inc., dated September 7, 2017 (incorporated by reference to Exhibit 10.5 to the Issuer’s Form 8-K (SEC File No. 001-37759), filed with the SEC on September 11, 2017).

 

4.Lock-Up Agreement by and among the Issuer, GMS Tenshi Holdings Pte. Limited and Pankaj Mohan, Ph.D, dated September 7, 2017 (incorporated by reference to Exhibit 10.8 to the Issuer’s Form 8-K (SEC File No. 001-37759), filed with the SEC on September 11, 2017).

 

5.Investor Rights Agreement by and between Oncobiologics, Inc. and GMS Tenshi Holdings Pte. Limited, dated September 11, 2017 (incorporated by reference to Exhibit 10.3 to the Issuer’s Form 8-K (SEC File No. 001-37759), filed with the SEC on September 11, 2017).

 

6.First Amendment to the Investor Rights Agreement (incorporated by reference to Exhibit 10.2 to the Issuer’s Form 8-K (SEC File No. 001-37759), filed with the SEC on May 15, 2018).

 

7.Exchange Agreement by and between Oncobiologics, Inc. and GMS Tenshi Holdings Pte. Limited, dated July 18, 2018 (incorporated by reference to Exhibit 10.1 to the Issuer’s Form 8-K (SEC File No. 001-37759), filed with the SEC on July 19, 2018).

 

8.Second Amendment to Investor Rights Agreement (incorporated by reference to Exhibit 10.2 to the Issuer’s Form 8-K (SEC File No. 001-37759), filed with the SEC on July 19, 2018).

 

 

 

 


CUSIP No. 68235M105		   Page    11   of      13   Pages

 

9.Purchase Agreement by and between the Issuer and BioLexis, dated November 5, 2018 (incorporated by reference to Exhibit 10.1 to the Issuer’s Form 8-K (SEC File No. 001-37759), filed with the SEC on November 9, 2018.

 

10.Third Amendment to Investor Rights Agreement (incorporated by reference to Exhibit 10.2 to the Issuer’s Form 8-K (SEC File No. 001-37759), filed with the SEC on November 9, 2018.

 

 

 

 


CUSIP No. 68235M105		   Page    12   of     13   Pages

 

Signatures

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: November 9, 2018

 

  BioLexis Pte. Ltd.  
       
       
  By:  /s/ Faisal G. Sukhtian  
  Name: Faisal G. Sukhtian  
  Title:  Director  
       
       
  Ghiath M. Sukhtian  
       
       
  /s/ Ghiath M. Sukhtian  
       
       
  Arun Kumar Pillai  
       
       
  /s/ Arun Kumar Pillai  

 

 

 

 

 

Schedule I

 

DIRECTORS AND EXECUTIVE OFFICERS OF

BioLexis Pte. Ltd.

 

The following tables set forth certain information with respect to the directors and executive officers of BioLexis Pte.Ltd.

 

Name, Business Address, Position   Principal Occupation   Citizenship
         

Faisal Ghiath Sukhtian

7th Circle, Zahran St., Zahran Plaza Building, 4th Floor

PO Box 142909

Amman, Jordan 11844

 

Position: Director

   Executive Director at GMS Holdings   Jordan
         

Kwik Poh Choo

5 Ewe Boon Road

Singapore 259316

 

Position: Director

   Director   Singapore
         

Kannan Pudhucode Radhakrishnan

# 30, “Galaxy”, 1st Main,

J.P. Nagar, 3rd Phase,

Bangalore, India 560078

 

Position: Director

   Director at Tenshi Life Sciences Private Limited   India
         

Lau Yim Chu Nancy

36 Robinson Road

#13-01

City House

Singapore 068877

 

Position: Corporate Secretary

   Corporate Secretary   British
         

 

 

 

EXHIBIT 1

  

JOINT FILING AGREEMENT

 

The undersigned hereby agree that this Statement on Schedule 13D, dated November 9, 2018 (the “Schedule 13D”), with respect to the common stock, par value $0.01 per share, of Oncobiologics, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, and that this Joint Filing Agreement (this “Agreement”) shall be included as an Exhibit to the Schedule 13D. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13D, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

 

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the 9th day of November, 2018.

 

  BioLexis Pte. Ltd.  
       
       
  By: /s/ Faisal G. Sukhtian  
  Name: Faisal G. Sukhtian  
  Title:  Director  
       
       
  Ghiath M. Sukhtian  
       
       
  /s/ Ghiath M. Sukhtian  
       
       
  Arun Kumar Pillai  
       
       
  /s/ Arun Kumar Pillai